KR101593242B1 - ６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법 - Google Patents
６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법 Download PDFInfo
- Publication number
- KR101593242B1 KR101593242B1 KR1020107008968A KR20107008968A KR101593242B1 KR 101593242 B1 KR101593242 B1 KR 101593242B1 KR 1020107008968 A KR1020107008968 A KR 1020107008968A KR 20107008968 A KR20107008968 A KR 20107008968A KR 101593242 B1 KR101593242 B1 KR 101593242B1
- Authority
- KR
- South Korea
- Prior art keywords
- halo
- optionally substituted
- alkyl
- mmol
- methyl
- Prior art date
Links
- VNBPTVUUYCWQRV-UHFFFAOYSA-N CC(C)(C)OC(NCc(cc1)cc2c1N=C(C)N(C(CCC(N1)=O)C1=O)C2=O)=O Chemical compound CC(C)(C)OC(NCc(cc1)cc2c1N=C(C)N(C(CCC(N1)=O)C1=O)C2=O)=O VNBPTVUUYCWQRV-UHFFFAOYSA-N 0.000 description 1
- LZQXGKFZKXVDQS-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc(c(Cl)ccc2)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc(c(Cl)ccc2)c2C1=O LZQXGKFZKXVDQS-UHFFFAOYSA-N 0.000 description 1
- UIUCFYZAMIWOSY-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc(ccc(Cl)c2)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc(ccc(Cl)c2)c2C1=O UIUCFYZAMIWOSY-UHFFFAOYSA-N 0.000 description 1
- MALNRQAZVXFDBU-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc(ccc(F)c2)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc(ccc(F)c2)c2C1=O MALNRQAZVXFDBU-UHFFFAOYSA-N 0.000 description 1
- JVKCFSMUWKKVAM-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2ccc(CNC(c3ccc(C(F)(F)F)cc3)=O)cc2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2ccc(CNC(c3ccc(C(F)(F)F)cc3)=O)cc2C1=O JVKCFSMUWKKVAM-UHFFFAOYSA-N 0.000 description 1
- FMGRSJDHPQPYBI-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2ccc(CNC(c3cccc(C(F)(F)F)c3)=O)cc2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2ccc(CNC(c3cccc(C(F)(F)F)c3)=O)cc2C1=O FMGRSJDHPQPYBI-UHFFFAOYSA-N 0.000 description 1
- OZWMRWXITLBHIL-UHFFFAOYSA-N O=C(CCC1N(C=Nc(c2c3)ccc3Br)C2=O)NC1=O Chemical compound O=C(CCC1N(C=Nc(c2c3)ccc3Br)C2=O)NC1=O OZWMRWXITLBHIL-UHFFFAOYSA-N 0.000 description 1
- SHSGQQNSSYEXIJ-UHFFFAOYSA-N O=C(CCC1N(C=Nc(cc2)c3cc2Cl)C3=O)NC1=O Chemical compound O=C(CCC1N(C=Nc(cc2)c3cc2Cl)C3=O)NC1=O SHSGQQNSSYEXIJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99567607P | 2007-09-26 | 2007-09-26 | |
| US60/995,676 | 2007-09-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100080540A KR20100080540A (ko) | 2010-07-08 |
| KR101593242B1 true KR101593242B1 (ko) | 2016-02-11 |
Family
ID=40225265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107008968A KR101593242B1 (ko) | 2007-09-26 | 2008-09-25 | ６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법 |
Country Status (22)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02420B (me) | 2006-09-26 | 2016-09-20 | Celgene Corp | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
| US8354417B2 (en) * | 2007-09-26 | 2013-01-15 | Celgene Corporation | Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
| AU2010286683B9 (en) * | 2009-08-31 | 2014-09-04 | Merck Sharp & Dohme Llc | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
| WO2011049731A1 (en) | 2009-10-21 | 2011-04-28 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| PL2683708T3 (pl) | 2011-03-11 | 2018-03-30 | Celgene Corporation | Postacie stałe 3-(5-amino-2-metylo-4-okso-4h-chinazolin-3-ylo)-piperydyno-2,6-dionu oraz ich kompozycje farmaceutyczne i zastosowania |
| DK2683384T3 (da) * | 2011-03-11 | 2016-02-08 | Celgene Corp | Fremgangsmåder til behandling af cancer under anvendelse af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| AU2014205043B2 (en) | 2013-01-14 | 2018-10-04 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| US9290475B2 (en) | 2013-03-14 | 2016-03-22 | Deuterx, Llc | 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
| MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| WO2014179661A1 (en) | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| HRP20230265T1 (hr) | 2014-08-22 | 2023-04-14 | Celgene Corporation | Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima |
| US10973822B2 (en) | 2015-07-02 | 2021-04-13 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| ES2839523T3 (es) * | 2016-01-14 | 2021-07-05 | Kangpu Biopharmaceuticals Ltd | Derivado de quinazolinona, procedimiento de preparación del mismo, composición farmacéutica y aplicaciones |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| KR102014478B1 (ko) * | 2017-05-12 | 2019-08-26 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| WO2018208123A1 (ko) * | 2017-05-12 | 2018-11-15 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| EP3679027A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydrobenzimidazolones |
| WO2019084452A1 (en) * | 2017-10-27 | 2019-05-02 | Transfusion Health, Llc | COMPOSITIONS AND METHODS FOR PRODUCING EXPANDED HEMATOPOIETIC STEM CELLS USING FLUORENE DERIVATIVES |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| BR112021019669A2 (pt) | 2019-04-12 | 2021-12-07 | C4 Therapeutics Inc | Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno |
| US11807620B2 (en) | 2020-02-21 | 2023-11-07 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| US20230303539A1 (en) * | 2020-08-14 | 2023-09-28 | Shanghaitech University | Immunoregulatory compound and antitumor application thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| DK0901487T3 (da) * | 1996-05-15 | 2003-08-25 | Pfizer | 2,3,6-trisubstituerede 4(3H)-quinazolinoner |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| DK0925294T6 (da) | 1996-07-24 | 2018-08-20 | Celgene Corp | Substituerede 2-(2,6-dioxopiperidin-3-yl)phthalimider og -1-oxoisoindoliner samt fremgangsmåde til reduktion af tnf-alpha-niveauer |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| KR100712573B1 (ko) * | 1998-03-16 | 2007-05-02 | 셀진 코포레이션 | 염증성 사이토카인 억제제용 2-(2,6-디옥소피페리딘-3-일)이소인돌린 유도체, 그 제조방법 및 그 용도 |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| WO2003041326A2 (en) | 2001-11-09 | 2003-05-15 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
| US7381730B2 (en) * | 2002-03-15 | 2008-06-03 | Bristol-Myers Squibb Company | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| AU2003256805A1 (en) * | 2002-07-23 | 2004-02-09 | Cytokinetics, Inc. | Compounds compositions and methods |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| EP1694328A4 (en) | 2003-12-02 | 2010-02-17 | Celgene Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| JP2007530544A (ja) | 2004-03-22 | 2007-11-01 | セルジーン・コーポレーション | 皮膚疾患又は障害を治療及び管理するための免疫調節化合物の使用方法及びそれを含む組成物 |
| NZ551004A (en) * | 2004-04-02 | 2010-07-30 | Prana Biotechnology Ltd | Neurologically-active compounds |
| JP2007533761A (ja) | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | 肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物 |
| US20080275022A1 (en) * | 2004-06-15 | 2008-11-06 | Astrazeneca Ab | Substituted Quinazolones as Anti-Cancer Agents |
| MX2007005570A (es) | 2004-11-12 | 2007-07-09 | Celgene Corp | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos. |
| ZA200704890B (en) | 2004-11-23 | 2008-09-25 | Celgene Corp | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| MX2007006439A (es) | 2004-12-01 | 2007-07-20 | Celgene Corp | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento de trastornos de inmunodeficiencia. |
| UA91560C2 (ru) | 2005-08-31 | 2010-08-10 | Селджин Корпорэйшн | Соединения ряда изоиндолимидов, их композиция и применение |
| EP2301535B1 (en) | 2005-09-01 | 2014-05-28 | Celgene Corporation | Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy |
| ME02420B (me) * | 2006-09-26 | 2016-09-20 | Celgene Corp | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
-
2008
- 2008-09-25 ES ES08834539.2T patent/ES2523925T3/es active Active
- 2008-09-25 EP EP08834539.2A patent/EP2200999B1/en active Active
- 2008-09-25 SG SG2011080553A patent/SG176442A1/en unknown
- 2008-09-25 BR BRPI0817525-0A2A patent/BRPI0817525A2/pt not_active Application Discontinuation
- 2008-09-25 AU AU2008305581A patent/AU2008305581C1/en not_active Ceased
- 2008-09-25 MY MYPI2010001343A patent/MY157495A/en unknown
- 2008-09-25 MX MX2010003355A patent/MX347987B/es active IP Right Grant
- 2008-09-25 US US12/238,354 patent/US8492395B2/en active Active
- 2008-09-25 CN CN201410362879.4A patent/CN104211684A/zh active Pending
- 2008-09-25 NZ NZ584425A patent/NZ584425A/en not_active IP Right Cessation
- 2008-09-25 KR KR1020107008968A patent/KR101593242B1/ko not_active IP Right Cessation
- 2008-09-25 WO PCT/US2008/011124 patent/WO2009042177A1/en active Application Filing
- 2008-09-25 CA CA2704710A patent/CA2704710C/en not_active Expired - Fee Related
- 2008-09-25 RU RU2010116273/04A patent/RU2476432C2/ru not_active IP Right Cessation
- 2008-09-25 CN CN200880117819.9A patent/CN101952272B/zh not_active Expired - Fee Related
- 2008-09-25 UA UAA201004853A patent/UA102078C2/ru unknown
- 2008-09-25 JP JP2010526944A patent/JP5637852B2/ja active Active
- 2008-09-25 SG SG10201503486XA patent/SG10201503486XA/en unknown
-
2010
- 2010-03-25 IL IL204763A patent/IL204763A/en active IP Right Grant
- 2010-03-25 NI NI201000041A patent/NI201000041A/es unknown
- 2010-03-31 ZA ZA2010/02303A patent/ZA201002303B/en unknown
- 2010-04-07 CR CR11355A patent/CR11355A/es unknown
- 2010-04-20 CO CO10046034A patent/CO6270228A2/es not_active Application Discontinuation
- 2010-07-05 HK HK10106484.8A patent/HK1139934A1/xx not_active IP Right Cessation
-
2013
- 2013-06-11 IL IL226870A patent/IL226870A/en active IP Right Grant
- 2013-06-26 US US13/928,147 patent/US9096573B2/en active Active
-
2015
- 2015-06-24 US US14/749,448 patent/US9586929B2/en active Active
-
2017
- 2017-01-25 US US15/415,332 patent/US9834538B2/en active Active
- 2017-11-07 US US15/806,254 patent/US20180118713A1/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| Acta Pharm.Suecica. vol.9, pp.431-446 (1972.) |
| Organic Chemistry and Pharmacology Departments Faculty of Pharmacy. Cairo, pp.273-284 (1976.) |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101593242B1 (ko) | ６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법 | |
| JP6133383B2 (ja) | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 | |
| RU2471794C2 (ru) | 4'-о-замещенные изоиндолиновые производные и содержащие их композиции и способы их применения | |
| RU2448101C2 (ru) | 5-замещенные изоиндолиновые соединения | |
| JP2011522803A (ja) | ５−置換イソインドリン化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| B701 | Decision to grant | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |